Therefore, targeting GABPB1 for anti-telomerase cancer therapy may counteract its tumor-suppressive activity, thereby promoting TC progression, which should be considered in the rational development of telomerase-based strategies against cancer. The gene discussed is GABPB1; the disease is cancer.